Workflow
债权债务化解
icon
Search documents
华仁药业股份有限公司2025年半年度报告摘要
Core Points - The company will not distribute cash dividends, issue bonus shares, or increase capital from reserves for the fiscal year 2024 due to reported losses [2][3] - The company plans to apply for a total credit limit of up to RMB 3.91 billion from various banks to meet operational and business development needs [4] - The company has fully provisioned for credit impairment losses on receivables from a subsidiary, and a debt resolution framework has been established with a counterparty, although execution remains uncertain [5] Company Overview - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [3] - There are no preferred shareholders or related shareholding situations reported for the period [3] Financial Information - The company has not needed to restate or adjust previous accounting data [2] - The company has not disclosed any changes in the number of shareholders or shareholding structure [2]